All the products are sold for laboratory use only, not for human consumption.

3-Methylmethcathinone (also known as 3-MMC or metaphedrone^[1]) is a novel stimulant–entactogen substance of the cathinone class. It is a structural analog of mephedrone (4-MMC). The mechanism of action is not fully studied, but dopamine and serotonin and norepinephrine releasing activity is known to be involved.

3-MMC first appeared on the online research chemical market shortly after the banning of the massively popular mephedrone. Its first emergence was recorded in Europe in 2012^[2]. It is a prominent example of a contemporary designer drug specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors.

Subjective effects include stimulation, anxiety suppression, disinhibition, enhanced empathy and sociability, relaxation, increased libido, and euphoria. The effects are reported to be similar to those of mephedrone, which is sometimes described as a hybrid of MDMA and cocaine.

However, it is described as being slightly less entactogenic and more stimulating than mephedrone, and some report more side effects. Like mephedrone and cocaine, it is associated with compulsive redosing and abuse due to its powerful, short-lived euphoric rush. It is typically administered via insufflation, although oral and injection routes have been observed.

Limited data exists about the pharmacological properties, metabolism, and toxicity of 3-MMC, and it has little history of human use.^{[citation needed]} Preliminary evidence suggests chronic use (i.e. high dose, repeat administration) may carry neurotoxic and cardiotoxic risks.^{[citation needed]} It is reported to produce the symptoms of serotonin depletion with overuse.

It is highly advised to use harm reduction practices if using this substance.